JP Morgan Maintains Neutral on Chemours, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 62.2%

Neg 0% Neu 0% Pos 62.2%

JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and raises the price target from $17 to $22.